A multicenter, epidemiological study of the treatment patterns, comorbidities and hypoglycemia events of patients with type 2 diabetes and moderate or severe chronic kidney disease – the ‘LEARN’ study

References

• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, 2013. Available at: http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures [Last accessed 5 May 2014]
   Google Scholar
• Zanchi A, Lehmannb R, Philippec J. Antidiabetic drugs and kidney disease. Swiss Med Wkly 2012;142:w13629
   PubMed Web of Science ®Google Scholar
• Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-50
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). CG73 Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. Available at: http://www.nice.org.uk/Guidance/CG73 [Last accessed 5 May 2014]
   Google Scholar
• Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-41
   PubMed Web of Science ®Google Scholar
• New JP, Middleton RJ, Klebe B, et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med 2007;24:364-9
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. USRDS 2007 annual data report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, 2007
   Google Scholar
• Fu AZ, Zhang Q, Davies MJ, et al. Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study. Curr Med Res Opin 2011;27:1035-40
   PubMed Web of Science ®Google Scholar
• Suh DC, Kim CM, Choi IS, et al. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004. J Hypertens 2009;27:1908-16
   PubMedGoogle Scholar
• Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest 2008;133:496-506
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85
   PubMed Web of Science ®Google Scholar
• Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41
   PubMed Web of Science ®Google Scholar
• Fox KM, Gerber RA, Bolinder B, et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95
   PubMed Web of Science ®Google Scholar
• Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther 2007;29:316-25
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S1-180
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Tuttle KR. Management of the diabetic patient with advanced chronic kidney disease. Semin Dial 2010;23:140-7
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-86
   PubMed Web of Science ®Google Scholar
• Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-7
   PubMed Web of Science ®Google Scholar
• Koukoulis GN, Sakka C, Katsaros F, et al. High rates of obesity prevalence in adults living in central Greece: data from the ARGOS study. Hormones (Athens) 2010;9:253-62
   PubMedGoogle Scholar
• Efstratopoulos AD, Voyaki SM, Baltas AA, et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens 2006;19:53-60
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Prevalence and five-year incidence (2001–2006) of cardiovascular disease risk factors in a Greek sample: the ATTICA study. Hellenic J Cardiol 2009;50:388-95
   PubMed Web of Science ®Google Scholar
• Andreoulakis E, Hyphantis T, Kandylis D, Iacovides A. Depression in diabetes mellitus: a comprehensive review. Hippokratia 2012;16:205-14
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;6:461-70
   Google Scholar
• Mendes AB, Fittipaldi JA, Neves RC, et al. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta Diabetol 2010;47:137-45
   PubMed Web of Science ®Google Scholar
• Moreira ED Jr, Neves RC, Nunes ZO. Glycemic control and its correlates in patients with diabetes in Venezuela: results from a nationwide survey. Diabetes Res Clin Pract 2010;87:407-14
   PubMed Web of Science ®Google Scholar
• Eligar VS, Bain SC. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug Design Develop Ther 2013;7:893-903
   PubMed Web of Science ®Google Scholar
• Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013;6:161-70
   PubMedGoogle Scholar
• Nogueira C, Souto SB, Vinha E, et al. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease. Hormones (Athens) 2013;12:483-94
   PubMedGoogle Scholar
• Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract 2012;40:7-21
   PubMedGoogle Scholar
• O’Toole SM, Fan SL, Yagoob MM, Chowdhury TA. Managing diabetes in dialysis patients. Postgrad Med J 2012;88:160-6
   PubMed Web of Science ®Google Scholar
• Ito H, Mifune M, Matsuyama E, et al. Vildagliptin is effective for glycemic control in diabetic patients undergoing either hemodialysis or peritoneal dialysis. Diabetes Ther 2013;4:321-9
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Foley JE, et al. Efficacy of vildagliptin in combination with insulin in patients with type2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-8
   PubMedGoogle Scholar
• Biesenbach G, Bodlaj G, Ebner S, et al. Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD. Int Urol Nephrol 2011;43:1155-60
   PubMed Web of Science ®Google Scholar
• Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis 2014;63:S22-38
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, sever hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diab 2007;25:90-7
   Google Scholar
• Inaba M, Okuno S, Kumeda Y, et al.; Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903
   PubMed Web of Science ®Google Scholar
• Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-8
   PubMed Web of Science ®Google Scholar
• Speeckaert M, Biesen WV, Delanghe J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant 2014;29:2167-77
   PubMed Web of Science ®Google Scholar
• Krosnick, JA, Alwin DP. An evaluation of a cognitive theory of response order effects in survey measurement. Pub Opin Quart 1987;51:201-19
   Web of Science ®Google Scholar
• Tourangeau R, Rips LJ, Rasinski K. The Psychology of Survey Response. Cambridge: Cambridge University Press, 2000
   Google Scholar
• Zintzaras E, Miligkos M, Ziakas P, et al. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clin Ther 2014;18:00430-5
   Google Scholar